Crohn's With Constipation, Not Diarrhea

Constipation is a recognised way for Crohn's disease to behave, not evidence that somebody got your diagnosis wrong. In a prospective survey of every newly diagnosed childhood IBD case reported across Great Britain and Ireland over 13 months, only a quarter of Crohn's cases arrived with the classic triad of diarrhoea, weight loss and abdominal pain, and nearly half did not report diarrhoea at all (Sawczenko 2003).

That is not a footnote. It is the reason this question keeps getting reposted in Crohn's communities, and the reason almost every page you have read on Crohn's symptoms was no use to you. Crohn's can involve any part of the gut from the mouth to the anus, it comes in inflammatory, stricturing and penetrating phenotypes, and up to a third of people develop perianal involvement (Feuerstein 2017). Those are four quite different plumbing problems wearing one name.

What follows is what constipation in Crohn's actually turns out to be, in what order those possibilities need ruling out, why the scoring systems your clinic uses cannot see your worst weeks, and what to write down so that the next appointment goes differently.

The short answer: it is real, and it is not one thing

Constipation in Crohn's is genuine, documented, and almost always a symptom of something more specific that has a name. The useful question is never "is this my Crohn's" but "which of the six or seven things that cause this in Crohn's is causing it in me", because the answer changes what should happen next in every direction at once.

That framing matters because the two errors people make here are mirror images. One is to assume constipation cannot be Crohn's, stop investigating, and treat it at home for two years. The other is to assume constipation is always a narrowing and live in fear of every meal. Both are common in the threads, and the way out of both is the same: get the cause characterised, then treat the cause.

Chronic constipation in the general population already has this structure. It is divided into primary disorders of normal transit, slow transit and defecation, and secondary constipation caused by medications or, more rarely, anatomical change. Straining, incomplete evacuation and a sense of anorectal blockage matter just as much as how often you go (Bharucha 2020). Crohn's adds structural narrowing and active inflammation to that list, and it adds them at the top, because they are the ones with a surgical endpoint.

How common is this, and why nobody can give you a straight number

Nobody can currently tell you what fraction of adults with Crohn's are constipation-predominant, because as far as we could find that study has not been done. What exists is a scatter of near misses, each in a different population, and the honest thing is to name them individually rather than average them into a fake number.

The strongest data on presentation is paediatric. Sawczenko and Sandhu surveyed 3,247 paediatricians, adult gastroenterologists and surgeons monthly for 13 months and captured 739 new childhood IBD cases. Nearly half of the Crohn's cases did not report diarrhoea, and the median delay from symptom onset to diagnosis was 5 months, with a fifth of children symptomatic for more than a year (Sawczenko 2003).

A more recent Italian study looked specifically at constipation before diagnosis. Of 238 children with IBD, 47 (19.7%) had a history of functional constipation before their IBD was identified, and 65% of those had been treated with macrogol for it. The constipation group waited longer for the diagnosis: a median of 5 months versus 2 months (Cenni 2025). Worth reading carefully, though: the finding about where the disease sat in the bowel reached significance only in the ulcerative colitis subgroup, where proctitis and left-sided disease were more common. It is not a Crohn's localisation finding, and any page that reports it as one has over-read the paper.

The constipation syndrome itself has been properly characterised only in ulcerative colitis. In a cross-sectional series of 125 people with UC, 58 (46%) met the authors' working definition of "proximal constipation": reduced stool frequency in 69%, hard stools in 43%, abdominal pain in 40%, excessive flatus in 29%, straining in 24% and a sensation of incomplete emptying in 14%. It was associated with female sex, left-sided disease and concurrently active disease, and 63% of that group were using laxatives or fibre supplements compared with 1.4% of everyone else (James 2018). The authors were explicit that their definition still needs validating. That is a UC paper, in a UC population, and there is no Crohn's equivalent of it. Do not let anyone hand you the 46% as a Crohn's figure.

Why "Crohn's means diarrhoea" is built into your notes

Part of the reason your symptom does not register is arithmetic. The instruments used to score Crohn's activity were designed around loose stools, and they have no way to record a day when nothing happened.

The Crohn's Disease Activity Index was built in the 1970s by collecting 18 candidate variables at 187 visits from 112 patients and running a regression against the attending physician's overall impression of how well each patient was doing. Eight variables survived into the final equation, with 150 as the cutoff between quiescent and active disease (Best 1976). The Harvey-Bradshaw Index, published in 1980 as a one-page simplification of it, scores a point for each liquid or soft stool with no upper limit and no item for the absence of one (Harvey 1980). The relationship between the two is close but loose: each HBI point predicts roughly a 27-unit change in CDAI, described by the statistician who built both as good but far from perfect (Best 2006). Our walkthrough of how to interpret a Harvey-Bradshaw score goes through each item and the traps in it.

Work through what that means for you. Someone with six liquid stools a day, mild pain and a slightly flat mood scores 8, which reads as moderate disease. Someone who has not opened their bowels for five days, is severely distended, vomited once from the pain and felt terrible all day scores 0 for stools, 3 for pain and 4 for well-being: 7, which reads as marginally better. The instrument is not lying, it is simply not measuring the thing that is wrong with you.

That is also why treat-to-target frameworks lean on markers rather than symptom scores. STRIDE-II sets symptomatic relief plus normalisation of blood and faecal markers as short-term targets, with clinical remission and endoscopic healing long-term, and notes that transmural healing in Crohn's is not a formal target but should be assessed as a measure of the depth of remission (Turner 2021). That consensus was produced by the International Organization for the Study of IBD, and the funders listed on the record include Bristol-Myers Squibb, Pfizer, Takeda, AbbVie, Janssen and Amgen.

One person in r/CrohnsDisease, a decade into remission on infliximab, described opening their bowels once every six or seven days and being told in effect that if it is not blood or diarrhoea, the clinic is happy (r/CrohnsDisease thread). That is not medical evidence, but it is a precise description of what happens when the measurement instrument has no box for your symptom.

The shortlist: six causes, and how they differ

Here is the whole list in one place, with what distinguishes each and what it would take to confirm it. This is the table to bring to an appointment, not a self-diagnosis exercise.

Two of those deserve their own sections, because they are the two that get missed.

Does constipation mean a stricture?

Not by itself, but this is the possibility that gets checked first, and it should be. Fibrotic stricture is a common complication affecting approximately half of all people with Crohn's. An interdisciplinary panel of 15 gastroenterologists and radiologists defined a fibrotic stricture as the combination of luminal narrowing, bowel wall thickening and dilation of the bowel upstream, judged magnetic resonance imaging the optimal technique for defining one, and described symptomatic strictures in terms of abdominal distension, cramping, dietary restriction, nausea, vomiting, abdominal pain and pain after eating (Rieder 2018). The grant record for that consensus lists the NIHR, the NIH and NIDDK.

Read that symptom list again. Constipation is not in it. What is in it is the constellation that people with a narrowing describe around their constipation: the distension, the post-meal pain, the shrinking food list. If your only symptom is going less often, with no pain, no distension and no nausea, a narrowing is less likely than the other five causes. If your constipation comes with cramping an hour after eating and a belly that swells through the day, that is the pattern worth naming out loud at your appointment.

The follow-through matters too. In a cohort of 86 adults with non-penetrating stricturing terminal ileal Crohn's, defined by centrally read MR enterography, 26% needed endoscopic balloon dilation or surgery within 12 months and 45% within 48 months. Obstructive symptoms, stricture length and stricture duration independently predicted the need for intervention, and biologic use was not associated with it (El Ouali 2022). Two caveats sit on that: 58.1% of the strictures were at a previous surgical anastomosis rather than in virgin bowel, and the study lists Pfizer alongside NIDDK and the NIH among its funders. It is also a terminal ileal cohort, so it says nothing about colonic narrowing.

On which scan, the evidence is more reassuring than the practice. A 2025 systematic review pooled 30 studies and 1,866 patients with small bowel Crohn's strictures against surgical histopathology, and found sensitivity and specificity of 0.88 and 0.86 for ultrasound, 0.82 and 0.80 for MR enterography and 0.83 and 0.77 for CT enterography, with no statistically significant difference between modalities (Dal Buono 2025). Two things temper that. The confidence interval around MRE's specificity ran from 0.44 to 0.95, which is wide enough to be nearly uninformative on its own. And the definitions were a mess: only 4 of 30 studies required all three of the standard descriptors, and 8 of 30 were judged at high or unclear risk of bias in at least one domain. The review excluded paediatric populations and colonic and upper gastrointestinal strictures, and reports no funding.

Pelvic floor dyssynergia: the cause almost nobody mentions

If your stool is soft or even normal and still will not come out, the problem may be coordination rather than content. Dyssynergic defecation, the failure of the rectal, abdominal and pelvic floor muscles to work together during defecation, is a major cause of constipation that does not respond to laxatives (Sharma 2022).

It has been looked for specifically in IBD. A group at a US centre evaluated IBD patients with persistent defecatory symptoms despite clinical improvement, using anorectal manometry with rectal sensory testing, a balloon expulsion test and simulated defecation. Of that group, 67% presented with constipation, and all but one met manometric criteria for dyssynergia. Among those who completed biofeedback, 30% achieved a clinically significant improvement in quality-of-life score, with reduced healthcare use over six months (p = 0.02) (Perera 2013).

Three honest caveats on that paper, because they matter more than the headline. It is tiny and uncontrolled, so the 30% has no comparison arm and cannot be read as an effect of biofeedback specifically. Everyone in it had been selected for having no left-sided disease, which is exactly how you enrich a sample for functional rather than inflammatory causes, so the near-universal dyssynergia rate is not a population estimate. And the arithmetic in the abstract does not add up: it reports 30 patients but then describes 23 with Crohn's and 6 with ulcerative colitis, which is 29, and the presentation percentages (67%, 10% and 6%) sum to 83 rather than 100. We could not reconcile either discrepancy from the abstract, and we are reporting the detail rather than smoothing it over.

The treatment side has the same shape. An Australian group offered up to six sessions of pelvic floor behavioural treatment to 34 people with quiescent IBD and persistent incontinence or constipation. Of the 29 who completed it, 21 (72%) rated themselves moderately or substantially improved, which is 62% of everyone who started. Symptom and illness-perception scores improved significantly, but general quality of life, anxiety and depression scores did not, and the transperineal ultrasound measures of pelvic floor activity did not correlate with how much better patients said they felt (Khera 2022). It was funded by the Australian Bladder Foundation. It also had no control group and an unblinded, patient-rated primary outcome, which is the design most likely to overstate benefit, and that last finding is a genuine puzzle: the physiological measure moved independently of the thing being treated.

Outside IBD the evidence is stronger but still uncontrolled. In 131 people with refractory chronic constipation who failed a balloon expulsion test, 81 responded to biofeedback, with dyssynergia and inadequate propulsion responding equally well and isolated structural pelvic floor abnormalities responding worse (Lambiase 2025). That population is not people with Crohn's, and there was no comparison arm, so read it as an indication that the treatment does something rather than a measure of how much.

What all of this adds up to practically is one sentence: if your stool is soft and still will not pass, ask whether anorectal testing is appropriate, because it is the one cause on the shortlist that no drug and no diet will touch.

Why you can feel blocked and pass loose stool at the same time

Because "needing to go" and "being able to empty" are two separate systems, and Crohn's can break either.

A thread asking whether anyone else feels constipated and has diarrhoea simultaneously drew a run of replies recognising it instantly, including one person who described sitting in agony from cramps with nothing coming out, occasionally vomiting from the pain before anything passed, and another who supplied the clinical word for a constant urge with little to pass: tenesmus (r/CrohnsDisease thread). Someone else offered the community's own coinage, "Crohnstipated", and noted it was most useful when they had strictures and adhesions.

There are at least three separate mechanisms behind that single experience, and they are worth telling apart:

• Liquid past a narrowing. A narrowed segment can still pass liquid while solid stool backs up behind it. That is why the NHS obstruction leaflet quoted above lists bursts of diarrhoea as a feature of an obstructive episode rather than a sign against one (UHSx 2026).
• Rectal inflammation generating the urge. An inflamed rectum reports "full" continuously regardless of what is in it. Feuerstein and Cheifetz note that up to a third of people with Crohn's develop perianal involvement (Feuerstein 2017), and several people in the constipation threads attributed their constipation directly to perianal or rectal inflammation that only settled when the inflammation was treated.
• An outlet that will not open. In dyssynergia, the urge and the content are both normal and the coordination is not, which produces the specific experience of straining hard against soft stool (Sharma 2022).

We could not find a study quantifying how often this combined pattern occurs in Crohn's, so treat the mechanisms as explanations and the frequency as unknown. What is not unknown is the action: a new pattern of feeling blocked with intermittent liquid output is a reason to be assessed, not a reason to alternate a laxative and an antidiarrhoeal at home.

Medication, and the iron and opioid questions

Secondary constipation from drugs is on the general shortlist for a reason (Bharucha 2020), and two candidates come up repeatedly in IBD.

Opioids are the clearest. Rome IV took opioid-induced constipation out of the functional bowel disorders and gave it its own category precisely because the mechanism is different (Mearin 2016). And opioid exposure in IBD is not rare: a population-based analysis of the Manitoba IBD Epidemiology Database found that within 10 years of diagnosis, 5% of people with IBD had become heavy opioid users, defined as continuous use for 30 days above 50 mg morphine equivalent daily. People with IBD were more likely than matched controls to reach that threshold (odds ratio 2.91, 95% CI 2.19 to 3.85), and heavy use was associated with excess mortality (odds ratio 2.82, 95% CI 1.58 to 5.02) (Targownik 2014). That mortality association is observational and almost certainly entangled with how severe someone's disease was in the first place, so it is not evidence that the drug killed anyone. It is evidence that this is a conversation to have with your team rather than a background detail.

Oral iron is the other. A meta-analysis of 43 randomised trials and 6,831 adults found ferrous sulfate significantly increased the odds of gastrointestinal side effects compared with placebo (odds ratio 2.32, 95% CI 1.74 to 3.08), with no relationship to dose (Tolkien 2015). That was adults in iron-deficiency trials generally, not people with Crohn's, and the analysis pooled gastrointestinal side effects rather than isolating constipation. It is a reason to ask, not a reason to stop: iron deficiency in Crohn's needs treating, and stopping a supplement on your own can cost you more than the constipation does. Nothing here is advice to start, stop or change any medicine.

Where the treatment evidence is, and where it runs out

There is a good guideline covering the drugs used for chronic constipation, and the reason it does not straightforwardly apply to you is worth understanding rather than working around.

The joint American Gastroenterological Association and American College of Gastroenterology guideline systematically reviewed fibre, osmotic laxatives, stimulant laxatives, secretagogues and a serotonin type 4 agonist, and issued strong recommendations for polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride, with conditional recommendations for fibre, lactulose, senna, magnesium oxide and lubiprostone (Chang 2023). Note the title: chronic idiopathic constipation. Idiopathic means no structural or secondary cause has been found, and in Crohn's that is exactly the thing that has not yet been established. The guideline is not wrong for you; it is simply downstream of a step you may not have taken. The grant record lists funders including the NIH, the US Food and Drug Administration, Takeda, Fondazione Roma and the International Foundation for Functional Gastrointestinal Disorders. We read the grant record rather than the individual authors' conflict statements, so we cannot tell you what those say.

It is also worth knowing how much of this field is unmeasured. Bharucha and Lacy state plainly that no studies have compared inexpensive laxatives with the newer drugs that work by different mechanisms (Bharucha 2020). So the sequencing your clinician offers is a judgement about cost and tolerability, not a ranked table of head-to-head results, and it is reasonable to ask them to explain the reasoning.

Fibre: the question with two correct opposite answers

Whether adding fibre helps or harms depends on a fact about your bowel that you may not have established yet, which is why the internet gives you a screaming argument instead of an answer.

In the cohort with the most relevant data, 1,619 participants in the Crohn's and Colitis Foundation of America Partners internet cohort who were in remission at baseline were followed for six months. Among those with Crohn's, the highest quartile of fibre intake was less likely to flare than the lowest (adjusted odds ratio 0.58, 95% CI 0.37 to 0.90), and people who said they did not avoid high-fibre foods were about 40% less likely to flare (adjusted odds ratio 0.59, 95% CI 0.43 to 0.81). There was no association in ulcerative colitis, where the point estimate actually ran the other way (adjusted odds ratio 1.82, 95% CI 0.92 to 3.60) (Brotherton 2016). The authors concluded that recommendations to limit dietary fibre should be re-evaluated.

That study cannot establish direction, and the paper's own findings show why: participants with longer disease duration, previous surgery and previous IBD hospitalisation ate less fibre. People with more damaged bowels avoid fibre because it hurts, and they also flare more. A self-selected internet cohort answering a 26-item dietary survey cannot separate those two stories. It was funded in part by the Crohn's and Colitis Foundation of America and the NIH.

The randomised evidence is older and narrower but points the same way. Seventy patients with non-stenosing Crohn's were randomly assigned to a low residue diet or a normal Italian diet for a mean of 29 months. Compliance was good and the fibre gap was large. There was no difference in symptoms, hospitalisation, need for surgery, new complications, nutritional status or post-operative recurrence, and lifting the restrictions did not precipitate intestinal obstruction. The detail that lands hardest: 86% of the people eating freely and 65% of those avoiding roughage had eliminated at least one permitted food anyway because of subjective intolerance (Levenstein 1985).

The word doing the work in that trial is "non-stenosing". It tells you that a blanket low-fibre diet is not protective in Crohn's without a narrowing. It tells you nothing about someone who has one, because those people were not in the study. That is the whole reason the fibre question has to go through imaging first. Our guide to what to eat during a Crohn's flare works through what low residue actually means and how strictures change the answer, and if you have had a resection or a stoma, the texture and chewing questions in our piece on foods that cause ileostomy blockage apply more directly than anything in the general Crohn's diet literature.

The two explanations that get over-sold

SIBO and methane. Several pages explain constipation in Crohn's by way of methane-producing bacterial overgrowth. The mechanism is plausible and the association is weaker than you would guess from how confidently it gets stated. In 79 consecutively tested constipated patients at a tertiary motility laboratory, neither baseline nor maximum breath methane on a glucose breath test correlated with total constipation symptom score, IBS severity score or bloating severity. Methane at the commonly used 3 and 5 ppm thresholds was equally distributed between the 79 constipated and 122 diarrhoea patients (Singh 2020). The same paper does report that baseline methane at 10 and 20 ppm or above correlated with having constipation, so it is not a clean null: severity did not track methane, but the presence of constipation did at higher cutoffs. Those are different claims and the paper makes both, so we are printing both. Overgrowth has its own ACG guideline covering diagnostic criteria, testing and treatment (Pimentel 2020), and our comparison of SIBO and IBS symptoms goes through why the breath test is contested.

Toilet posture. The footstool has better data behind it than most home remedies, in the wrong population. Fifty-two healthy volunteers, mean age 29, recorded 1,119 bowel movements over four weeks, the first two without a posture-modification device and the next two with. Using it was associated with greater sense of complete emptying (odds ratio 3.64, 95% CI 2.78 to 4.77) and less straining (odds ratio 0.23, 95% CI 0.18 to 0.30) (Modi 2019). These were healthy volunteers rather than people with Crohn's, nobody was blinded, and the order was fixed rather than randomised, so novelty and increased attention to bowel habit are not excluded. It is cheap and harmless, which is a fair reason to try it, and it is not a treatment for a narrowing.

When it is not your Crohn's at all

Constipation in someone with Crohn's can be plain coexisting constipation, and that possibility gets less attention than it should because both patient and clinician are primed to blame the diagnosis in the room.

The overlap is large. A meta-analysis of 27 studies and 3,169 people with IBD in remission found pooled IBS-type symptom prevalence of 32.5%, higher in Crohn's (36.6%) than in ulcerative colitis (28.7%), and still around a quarter when remission had been confirmed endoscopically (23.5%) (Fairbrass 2020). That review reports no funding. So roughly one in three people with Crohn's in remission has symptoms that meet criteria for a disorder of gut-brain interaction, and in a subset the predominant pattern will be constipation.

The longitudinal follow-up is more interesting still. Among 125 people with IBD assessed with Rome III criteria at baseline, two years and six years, only 41 (32.8%) never reported IBS-type symptoms at any point. Symptoms came and went: 12.0% resolved, 15.2% fluctuated, 28.0% were new-onset and 12.0% were persistent. Those symptoms were associated with more outpatient appointments and more endoscopies, and with worse anxiety, depression, somatoform and quality-of-life scores, but not with any increase in flares, steroid courses, treatment escalation, hospitalisation or surgery (Fairbrass 2022). That is a genuinely reassuring negative finding and also a warning: these symptoms drive a lot of investigation without predicting a worse disease course.

The reason this still needs a proper look rather than a shrug is that you cannot tell the difference by feel. Inflammation and symptoms come apart in both directions in Crohn's, which is why our piece on high calprotectin with no symptoms exists at all, and why our guide to telling whether you are in a Crohn's flare puts tests rather than symptom scores at the centre. If you also swing between constipation and looseness within the same week, the mechanics in our guide to managing IBS-M may describe your pattern better than anything in the Crohn's literature, provided active inflammation and narrowing have been excluded first.

Worth flagging separately: many people in the constipation threads describe nausea, malaise and heavy fatigue in the days before anything moves. We could not find any study measuring that specific sequence in Crohn's, so it belongs in the widely-reported column rather than the evidence column. Fatigue in Crohn's does have documented explanations that are worth working through, which our piece on Crohn's fatigue in remission covers, and symptoms outside the gut have their own recognised framework, set out in our guide to joint pain with Crohn's disease.

What a proper work-up looks like

The sequence matters more than any individual test, and it runs from the most consequential possibility to the least.

1. Rule the narrowing in or out. That means cross-sectional imaging, not a symptom score. MRI was judged the optimal technique by the stricture consensus panel (Rieder 2018), and the pooled accuracy data suggest ultrasound, MRE and CTE perform comparably for small bowel strictures (Dal Buono 2025). Europe's IBD, radiology, pathology and bowel ultrasound societies now publish a joint guideline covering initial diagnosis, the detection of complications and the use of monitoring tools (Kucharzik 2025), which is the document your team is working from.
2. Look at the distal bowel and the perineum. Rectal and perianal disease is common enough in Crohn's that it should be examined for rather than inferred (Feuerstein 2017).
3. Check the inflammation question objectively. Faecal and blood markers are short-term treat-to-target endpoints, and normalising them is an explicit goal (Turner 2021). One honest gap: we found no study measuring faecal calprotectin specifically in constipation-predominant Crohn's, so nobody can tell you how a normal result should be weighted when constipation is your main symptom.
4. Review every medicine and supplement. Including anything bought over the counter.
5. Then, and only then, test the outlet. Anorectal tests are recommended in people who do not respond to over-the-counter agents (Bharucha 2020), and manometry plus balloon expulsion is what identifies dyssynergia (Sharma 2022). One practical note from the biofeedback literature: a straining questionnaire and a digital rectal examination augmented by abdominal palpation correlated strongly with who responds, so a good bedside examination is not a poor substitute for testing but a reasonable first filter (Lambiase 2025).

Delay is not free

The argument for pushing on this rather than accepting it is measurable. In the Swiss IBD Cohort Study, 387 paediatric and 1,163 adult Crohn's patients were analysed. The median diagnostic delay was 3 months (IQR 1 to 9) for children and 6 months (IQR 1 to 24) for adults, and adults presented at diagnosis more frequently with bowel stenosis and with surgery. Crucially, the length of diagnostic delay predicted Crohn's-related complications in the adult population but not the paediatric one (Schoepfer 2019). The study was funded by the Swiss National Science Foundation.

That is about delay to diagnosis rather than delay in characterising a symptom in someone already diagnosed, so do not stretch it further than it goes. But it points the same way as the Italian paediatric data, where a history of functional constipation was associated with a longer wait for the IBD diagnosis (Cenni 2025): when the presentation does not look like the textbook, things take longer, and taking longer costs something.

What to log when the problem is that nothing is happening

Standard symptom tracking is built for the opposite problem. Here is what actually carries information when constipation is your pattern, and it is deliberately short, because a log you abandon in a week is worth nothing.

A month of that fits on one side of paper and answers questions a score of 4 cannot. Our guide to handing a symptom record to a clinician covers the formats that survive a short appointment, and if you would rather the arithmetic happened for you, Clairop logs a bowel movement as one tap on the Bristol scale with straining and urgency as optional detail underneath, and produces a one-page summary to take with you; how it works walks through it. It is a record-keeping tool, not a diagnostic one, and the causes on the shortlist above are all identified by tests rather than by logs.

A worked example: two people, one complaint

Person A has ileal Crohn's, one previous resection, and has opened her bowels twice in the past week. Both times it was type 2, with hard straining. She has cramping pain roughly an hour after lunch most days, a belly that is visibly bigger by evening and flat by morning, and she stopped eating salad, nuts and raw apple two years ago because of how they felt going through. She has lost no weight and has no bleeding.

Her pattern maps onto the obstructive description almost item for item: distension, cramping, dietary restriction, post-prandial pain (Rieder 2018). The appropriate next step is imaging, and the fibre conversation cannot sensibly happen before the imaging result, because the trial showing fibre restriction is unnecessary in Crohn's excluded people with stenosis (Levenstein 1985). Escalating a laxative here without imaging would be treating the symptom while the relevant question stayed open.

Person B has Crohn's colitis, is four years into remission on a biologic with a recently normal calprotectin, and goes every five or six days. His stool is soft when it arrives, type 4 or 5, and the problem is that he strains for twenty minutes and then feels he has not finished. No post-meal pain, no vomiting, no weight change, no distension pattern.

Two identical letters would read "constipation in Crohn's". But soft stool that will not pass in confirmed remission is the description of an outlet problem, and that is the group anorectal testing exists for (Perera 2013; Sharma 2022). Laxatives address the consistency of stool that is already soft enough. His question at the next appointment is about manometry and a balloon expulsion test, not about a stronger laxative.

Same symptom, same diagnosis, opposite next steps. That is the whole reason the shortlist matters.

Myths worth retiring

"Crohn's causes diarrhoea, so this cannot be my Crohn's." Nearly half of newly diagnosed children in a national survey did not report diarrhoea, and only a quarter had the full classic triad (Sawczenko 2003).

"Constipation always means a stricture." It does not, and the symptom set attached to a symptomatic stricture is distension, cramping, dietary restriction, nausea, vomiting and post-meal pain rather than reduced frequency alone (Rieder 2018). It is the first thing to exclude, not the default conclusion.

"If my calprotectin is normal and my scope was clean, this is just IBS." Sometimes it is, and roughly a third of people with Crohn's in remission report IBS-type symptoms (Fairbrass 2020). But dyssynergia is a separate, testable, treatable cause of the same complaint in remission (Perera 2013), and a fibrotic narrowing is a structural problem that a stool marker was never designed to detect.

"Low fibre is the safe default in Crohn's." In non-stenosing Crohn's, a randomised trial found low residue no better than a normal diet on symptoms, surgery, hospitalisation, nutrition or recurrence, and lifting restrictions did not precipitate obstruction (Levenstein 1985). In a cohort of people in remission, fibre avoidance went with more flares in Crohn's, though not in UC, where the estimate ran the opposite way (Brotherton 2016). With a known stricture the calculation is different, and that is a conversation for your team.

"Methane overgrowth explains my constipation." Breath methane did not correlate with constipation severity or bloating in 79 constipated patients, and low-threshold methane was equally common in constipation and diarrhoea, although higher baseline thresholds did associate with having constipation (Singh 2020). It is an unsettled question presented online as a settled one.

"Biofeedback is proven to fix this in IBD." The IBD studies are single-arm series of 30 and 34 people with unblinded, patient-rated outcomes, one of which found no change in quality of life, anxiety or depression and no correlation between the physiological measure and how much better patients said they felt (Perera 2013; Khera 2022). It is promising and worth asking about. It is not proven.

"Getting this looked at is making a fuss." In the Swiss cohort, the length of diagnostic delay predicted complications in adults with Crohn's (Schoepfer 2019), and in the paediatric Italian series a constipation history went with a longer wait for diagnosis (Cenni 2025). An atypical presentation is a reason to be more insistent, not less.

When to see a doctor promptly

Contact your IBD team or seek urgent care the same day for any of the following:

• Severe cramping pain with a distended, tender abdomen, repeated vomiting, and no wind or stool passing. This can indicate an obstruction, and the NHS leaflet quoted above tells patients to go to hospital for persistent vomiting or severe abdominal pain (UHSx 2026).
• Vomiting food eaten hours earlier, or being unable to keep fluids down.
• New or increasing blood in your stool, or bleeding where there was none before.
• Unexplained weight loss, fever, drenching night sweats, or new anaemia symptoms such as breathlessness and dizziness.
• A complete change in your pattern that has lasted more than a week or two, including going from your usual looseness to nothing at all.
• Severe pain on opening your bowels, or a new lump, discharge or swelling near the anus. Perianal disease needs assessing rather than managing at home.
• Any of the classic red flags at any time: night-time symptoms waking you, symptoms starting after 50, or a family history of bowel cancer or IBD. See a doctor promptly rather than waiting for a routine review.

And a softer trigger that is still worth acting on: if you have been managing this yourself with over-the-counter products for months, or you have a bowel pattern you have stopped mentioning because nobody seemed interested, that is a reason to bring it up explicitly. Our list of questions to ask your doctor about Crohn's is a reasonable place to start building the conversation.

The honest bottom line

Constipation in Crohn's is real, it is documented, and it is the presentation the entire internet was written past. It is also not a diagnosis. It is a symptom with a short, ordered list of causes: a narrowing, distal or perianal inflammation, a pelvic floor that will not coordinate, a medicine, a diet you adopted years ago for a different problem, and coexisting IBS-type symptoms. Those are distinguished by imaging, examination, markers, a medication review and anorectal testing, in roughly that order, and they are treated in five different ways.

What we could not find matters too. There is no adult prevalence figure for constipation-predominant Crohn's. The constipation syndrome has been characterised in ulcerative colitis and not in Crohn's. Nobody has measured calprotectin specifically in this group. The biofeedback evidence in IBD is two small uncontrolled series. And the drug guideline everyone reaches for is written for constipation with no structural cause, which is precisely the thing that needs establishing first.

The practical version fits in three lines. Write down days since your last bowel movement, Bristol type, straining, whether you felt empty, and when pain arrives relative to eating. Say the words "obstructive symptoms" and "anorectal testing" at your next appointment, because both are terms that trigger a defined pathway. And treat any combination of severe pain, distension, vomiting and nothing passing as a same-day problem rather than a bad week.